EASL Congress 2025
Amsterdam, The Netherlands, 07 - 10 May 2025
We are excited to announce our participation in the EASL Congress 2025, taking place from May 7–10 at the RAI Amsterdam. This prestigious event gathers over 8,000 international delegates, offering a unique platform for scientific exchange, collaboration, and learning.
Owlstone Medical will also be exhibiting at the conference. We invite you to visit us to discuss how our Breath Biopsy® platform can support your biomarker discovery research.
Our pioneering work in breath analysis includes developing a breath test capable of detecting liver disease early, before symptoms appear. This innovative approach uses an Exogenous Volatile Organic Compound (EVOC®) Probe, specifically limonene, to assess liver function. Our research has shown promising results, indicating that breath testing could serve as an effective screening tool for liver disease in both children and adults. We look forward to sharing our latest advancements and engaging with the global hepatology community at EASL 2025.
If you have any questions, or would like to schedule a meeting, contact us.
Dr Ben Constant
Dr Ben Constant is a Business Development Executive at Owlstone Medical, where he is dedicated to advancing breath biomarker research.
Ben completed his undergraduate studies in Biomedical Sciences at the University of Sheffield, before pursuing a PhD at the University of Cambridge under the supervision of Dr Wei Li in the Department of Medicine. His doctoral research focused on elucidating the mechanisms of action of a novel pharmaceutical treatment for obesity.
Ben has a diverse background in the medical technology sector. He previously worked at Ortho Clinical Diagnostics, where he contributed to the development of a diagnostic test for heart attacks. Additionally, he has served as a technical consultant, assisting MedTech innovators in bringing their cutting-edge technologies to market.
In his current role, Ben is passionate about collaborating with leading scientists across Europe and Asia, helping them explore how breath biomarkers can enhance their research and clinical outcomes.
